Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sarepta Therapeutics鈥� SEC disclosures often means sifting through pages on exon skipping science, gene therapy batch yields, and multi-year cash burn tables. If you鈥檝e ever typed 鈥淪arepta Therapeutics SEC filings explained simply鈥� into a search bar, you already know the challenge. Stock Titan鈥檚 AI tackles that complexity head-on, turning dense research updates into plain-English highlights that focus on Duchenne muscular dystrophy trials, FDA milestones, and collaboration revenue streams.
Need the numbers fast? Our platform pulls every 鈥淪arepta Therapeutics quarterly earnings report 10-Q filing鈥� as soon as it hits EDGAR and pairs it with instant ratio analysis. AG真人官方-time alerts for 鈥淪arepta Therapeutics Form 4 insider transactions real-time鈥� let you see when directors buy ahead of pivotal readouts. Use AI-powered summaries to move from headline to detail across all major forms:
- Sarepta Therapeutics annual report 10-K simplified鈥攃ash runway, pipeline probability tables, and manufacturing capacity.
- Sarepta Therapeutics proxy statement executive compensation鈥攃ompare leadership incentives to clinical milestones.
- Sarepta Therapeutics 8-K material events explained鈥擣DA decisions, partnership payments, or safety updates within minutes.
The result: one page that answers the questions investors actually ask鈥斺�淗ow did Exondys 51 sales shift this quarter?鈥� or 鈥淲hat do Sarepta Therapeutics insider trading Form 4 transactions signal ahead of an FDA advisory meeting?鈥� Whether you鈥檙e tracking 鈥淪arepta Therapeutics executive stock transactions Form 4鈥� or need a deep 鈥淪arepta Therapeutics earnings report filing analysis,鈥� our AI shows you the story behind the numbers. Start 鈥渦nderstanding Sarepta Therapeutics SEC documents with AI鈥� today and make faster calls on gene-therapy breakthroughs without reading hundreds of pages first.
Sarepta Therapeutics (SRPT) Form 4 filing: Chief Technology Operations Officer Bilal Arif reported the award of 6,250 Performance Stock Units (PSUs) on 08/05/2025. The grant originates from a March 1 2024 PSU agreement; shares earned were approved by the Compensation Committee based on milestone achievement. The PSUs convert 1-for-1 into common stock and will vest on 03/01/2026, contingent on continued employment. Following the transaction, Arif directly holds 6,250 derivative securities; no shares were sold and no cash price was paid, indicating this is an incentive, not a market purchase. No changes to common-stock ownership were disclosed.
The filing signals ongoing executive retention and alignment with long-term performance targets but does not materially affect share count or near-term earnings. Investors typically view such equity awards as neutral unless unusually large relative to existing float.
Insider award: On 08/05/2025 Sarepta Therapeutics (SRPT) President of R&D and Tech Ops, Louise Rodino-Klapac, earned 6,250 Performance Stock Units (PSUs) according to a Form 4 filing. The PSUs stem from a grant dated 03/01/2024 and were unlocked after the Compensation Committee confirmed the company met specific milestones. No cash was paid (exercise price $0) and there were no share sales or disposals. All 6,250 PSUs remain un-vested and are scheduled to vest on 03/01/2026, contingent on continued employment. Following the transaction the executive beneficially owns 6,250 derivative securities directly. The filing signals milestone achievement but represents a small ownership change relative to Sarepta鈥檚 total share count, implying limited dilution or immediate market impact.
SRPT Form 4: routine tax-withholding sale
On 07/31/2025, Sarepta Therapeutics (SRPT) Chief Financial Officer Ryan Ho-Yan Wong reported the disposition of 327 common shares at $16.42 under transaction code 鈥淔,鈥� which denotes shares surrendered to the company solely to satisfy payroll-tax obligations triggered by vesting of RSUs granted 07/30/2021. After the withholding transaction, Wong directly holds 17,328 SRPT shares; no derivative positions were listed.
The filing reflects a non-discretionary, tax-related share reduction rather than an open-market sale, and therefore carries limited signaling value regarding insider sentiment or the firm鈥檚 fundamentals.
Sarepta Therapeutics (SRPT) Form 3 records newly appointed CFO Ryan Ho-Yan Wong鈥檚 initial beneficial ownership as of 16 Jul 2025. He directly holds 17,655 common shares. The filing also lists 11 stock-option grants covering 31,031 shares with exercise prices between $67.78 and $155.99 and expirations from 2031-2035; each grant vests 25 % at the first anniversary and then monthly. No shares were bought or sold鈥攖his is a baseline disclosure required under Section 16(a). The document contains no operating, financial, or strategic updates and is unlikely to affect the investment thesis for SRPT.
D. E. Shaw & Co., L.P. and founder David E. Shaw filed Amendment No. 1 to Schedule 13G disclosing a passive 5.1 % holding (5,059,912 shares) in Sarepta Therapeutics (SRPT) as of 18 Jul 2025. The stake is spread across three internal vehicles: D. E. Shaw Valence Portfolios (2.78 m shares), D. E. Shaw Oculus Portfolios (1.39 m) and accounts managed by D. E. Shaw Investment Management (0.89 m).
The reporting persons have shared voting power over 5,000,212 shares and shared dispositive power over the full 5,059,912 shares; they possess no sole voting or dispositive authority. The filing is made under Rule 13d-1(b) as an investment adviser and states the shares were not acquired to influence control of the issuer.
This amendment corrects the original 13G by attaching the Joint Filing Agreement dated 25 Jul 2025; no changes to ownership levels or intent are reported.
FAQ
What is the current stock price of Sarepta Therapeutics (SRPT)?
What is the market cap of Sarepta Therapeutics (SRPT)?
